## Rash

## TABLE 141: RASH TREATMENT-NAIVE: RELATIVE RISKS AND RISK DIFFERENCE FOR ALL TREATMENT COMPARISONS — RANDOM EFFECTS MODEL

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF12 + RBV12	PR48	0.52 (0.17 to 1.60)	-8.48 (-16.10 to 10.73)
SOF24 + RBV24		0.77 (0.08 to 2.72)	-4.22 (-17.46 to 31.63)
SOF12 + LDV12		0.26 (0.14 to 0.48)	-13.27 (-17.51 to -8.82)
SOF8 + LDV8 + RBV8		0.96 (0.31 to 2.32)	-0.78 (-12.87 to 24.01)
SOF12 + LDV12 + RBV12		0.39 (0.20 to 0.75)	-10.98 (-15.81 to -4.35)
SOF24 + LDV24 + RBV24		0.49 (0.26 to 0.93)	-9.21 (-14.51 to -1.29)
T12 PR24-48 RGT q8		1.58 (1.04 to 2.26)	10.49 (0.67 to 22.88)
T12 PR24-48 RGT q12		1.49 (0.84 to 2.31)	8.87 (-2.88 to 23.75)
T12 PR48 q8		2.52 (1.41 to 4.03)	27.82 (7.86 to 51.33)
SOF12 + PR12		0.80 (0.37 to 1.77)	-3.60 (-11.93 to 13.85)
SOF12 PR24-48 RGT		1.60 (0.79 to 2.96)	10.88 (-4.00 to 32.53)
SIM12 PR24-48 RGT		1.12 (0.81 to 1.52)	2.15 (-3.61 to 9.16)
B24 PR28-48 RGT		1.11 (0.70 to 1.68)	1.98 (-5.63 to 12.37)
B44 PR48		2.75 (0.63 to 5.71)	32.19 (-7.14 to 72.86)
PR24		1.03 (0.31 to 2.84)	0.55 (-12.93 to 33.05)
SOF24 + RBV (low dose) 24		0.06 (0.01 to 0.35)	-16.75 (-20.81 to - 11.03)
PAR/RIT12 + OMB12 + DAS12		0.22 (0.09 to 0.53)	-14.03 (-18.22 to -8.34)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.72 (0.38 to 1.30)	-5.05 (-11.99 to 5.31)
DCV24 + ASU24		0.13 (0.05 to 0.32)	-15.69 (-19.48 to - 11.41)
DCV12 + SOF12		0.37 (0.05 to 1.61)	-11.36 (-18.70 to 10.80)
SOF24 + RBV24	SOF12 + RBV12	1.44 (0.15 to 6.01)	3.83 (-16.91 to 38.02)
SOF12 + LDV12		0.50 (0.19 to 1.32)	-4.71 (-22.33 to 1.18)
SOF8 + LDV8 + RBV8		1.78 (0.47 to 6.27)	7.12 (-11.65 to 31.28)
SOF12 + LDV12 + RBV12		0.74 (0.23 to 2.39)	-2.43 (-20.88 to 5.59)
SOF24 + LDV24 + RBV24		0.93 (0.29 to 3.02)	-0.68 (-19.08 to 8.19)
T12 PR24-48 RGT q8		2.99 (0.92 to 9.63)	18.67 (-2.28 to 33.02)
T12 PR24-48 RGT q12		2.81 (0.81 to 9.21)	16.92 (-4.90 to 33.58)
T12 PR48 q8		4.75 (1.47 to 15.71)	35.64 (10.40 to 59.93)
SOF12 + PR12		1.54 (0.69 to 3.43)	4.78 (-6.45 to 15.25)
SOF12 PR24-48 RGT		2.99 (0.84 to 11.07)	18.83 (-3.82 to 41.48)
SIM12 PR24-48 RGT		2.12 (0.67 to 6.97)	10.45 (-9.31 to 20.94)
B24 PR28-48 RGT		2.09 (0.62 to 6.98)	10.23 (-10.20 to 22.84)
B44 PR48		4.86 (0.85 to 20.77)	39.18 (-2.70 to 81.22)
PR24		1.92 (1.08 to 3.31)	8.67 (0.74 to 27.49)
SOF24 + RBV (low dose) 24		0.13 (0.01 to 0.61)	-8.07 (-25.98 to -1.70)
PAR/RIT12 + OMB12 + DAS12		0.42 (0.10 to 1.72)	-5.42 (-24.78 to 2.81)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.35 (0.43 to 4.27)	3.21 (-14.45 to 14.25)
DCV24 + ASU24		0.24 (0.05 to 1.10)	-7.05 (-26.39 to 0.37)
DCV12 + SOF12		0.68 (0.08 to 4.56)	-2.88 (-22.52 to 19.46)
SOF12 + LDV12	SOF24 + RBV24	0.34 (0.10 to 3.38)	-8.95 (-44.08 to 3.60)
SOF8 + LDV8 + RBV8		1.27 (0.26 to 13.24)	3.35 (-31.63 to 28.95)
SOF12 + LDV12 + RBV12		0.52 (0.14 to 5.22)	-6.50 (-41.85 to 7.10)
SOF24 + LDV24 + RBV24		0.66 (0.17 to 6.79)	-4.58 (-39.93 to 9.44)
T12 PR24-48 RGT q8		2.05 (0.53 to 20.05)	14.24 (-22.70 to 33.77)
T12 PR24-48 RGT q12		1.92 (0.47 to 19.27)	12.41 (-25.19 to 34.43)
T12 PR48 q8		3.30 (0.79 to 35.88)	30.85 (-9.54 to 59.33)
SOF12 + PR12		1.08 (0.28 to 10.51)	1.00 (-31.94 to 21.13)
SOF12 PR24-48 RGT		2.17 (0.48 to 17.93)	15.10 (-24.61 to 41.10)
SIM12 PR24-48 RGT		1.45 (0.39 to 14.60)	6.13 (-30.09 to 21.62)
B24 PR28-48 RGT		1.45 (0.38 to 14.29)	6.00 (-29.62 to 22.94)
B44 PR48		3.54 (0.55 to 33.81)	33.61 (-14.73 to 78.96)
PR24		1.37 (0.30 to 13.01)	4.44 (-28.65 to 37.99)
SOF24 + RBV (low dose) 24		0.09 (0.01 to 0.60)	-12.15 (-47.90 to -0.68)
PAR/RIT12 + OMB12 + DAS12		0.29 (0.06 to 2.99)	-9.63 (-46.10 to 4.01)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.95 (0.23 to 9.36)	-0.71 (-36.53 to 14.96)
DCV24 + ASU24		0.17 (0.03 to 2.01)	-11.31 (-47.86 to 1.73)
DCV12 + SOF12		0.51 (0.05 to 6.45)	-6.20 (-42.18 to 17.12)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF8 + LDV8 + RBV8	SOF12 + LDV12	3.60 (1.43 to 7.96)	12.45 (1.77 to 36.09)
SOF12 + LDV12 + RBV12		1.49 (0.75 to 2.97)	2.22 (-1.61 to 8.15)
SOF24 + LDV24 + RBV24		1.86 (0.94 to 3.69)	4.04 (-0.37 to 11.22)
T12 PR24-48 RGT q8		6.03 (2.90 to 11.99)	23.81 (13.00 to 36.86)
T12 PR24-48 RGT q12		5.67 (2.46 to 11.81)	22.11 (9.51 to 37.83)
T12 PR48 q8		9.54 (4.52 to 19.38)	41.21 (21.44 to 63.92)
SOF12 + PR12		3.08 (1.82 to 5.37)	9.82 (3.33 to 24.82)
SOF12 PR24-48 RGT		6.08 (2.36 to 14.29)	24.28 (9.09 to 45.21)
SIM12 PR24-48 RGT		4.27 (2.13 to 8.55)	15.46 (8.42 to 23.42)
B24 PR28-48 RGT		4.24 (1.96 to 8.77)	15.26 (6.70 to 26.46)
B44 PR48		10.14 (2.09 to 28.19)	45.53 (6.59 to 84.78)
PR24		3.92 (1.36 to 9.87)	13.81 (1.61 to 44.82)
SOF24 + RBV (low dose) 24		0.25 (0.04 to 1.27)	-3.33 (-7.12 to 1.19)
PAR/RIT12 + OMB12 + DAS12		0.85 (0.28 to 2.39)	-0.71 (-5.27 to 5.07)
PAR/RIT12 + OMB12 + DAS12 + RBV12		2.74 (1.42 to 5.22)	8.19 (2.36 to 17.36)
DCV24 + ASU24		0.49 (0.15 to 1.55)	-2.33 (-6.68 to 1.80)
DCV12 + SOF12		1.41 (0.18 to 6.40)	1.89 (-5.23 to 23.67)
SOF12 + LDV12 + RBV12	SOF8 + LDV8 + RBV8	0.41 (0.15 to 1.32)	-9.98 (-34.65 to 2.21)
SOF24 + LDV24 + RBV24		0.52 (0.18 to 1.60)	-8.24 (-32.88 to 4.33)
T12 PR24-48 RGT q8		1.64 (0.63 to 5.23)	11.05 (-14.74 to 28.53)
T12 PR24-48 RGT q12		1.54 (0.55 to 5.04)	9.36 (-17.09 to 29.02)
T12 PR48 q8		2.63 (0.94 to 8.63)	28.02 (-2.16 to 54.66)
SOF12 + PR12		0.85 (0.33 to 2.56)	-2.44 (-24.25 to 13.84)
SOF12 PR24-48 RGT		1.67 (0.55 to 6.25)	11.40 (-16.95 to 37.12)
SIM12 PR24-48 RGT		1.17 (0.45 to 3.73)	2.85 (-22.07 to 17.13)
B24 PR28-48 RGT		1.16 (0.42 to 3.78)	2.81 (-23.08 to 18.89)
B44 PR48		2.82 (0.53 to 11.13)	31.74 (-13.74 to 75.23)
PR24		1.08 (0.29 to 4.09)	1.24 (-23.87 to 32.49)
SOF24 + RBV (low dose) 24		0.07 (0.01 to 0.46)	-15.76 (-40.51 to -3.84)
PAR/RIT12 + OMB12 + DAS12		0.23 (0.06 to 0.92)	-13.07 (-38.28 to -0.55)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.75 (0.28 to 2.25)	-4.10 (-28.09 to 9.15)
DCV24 + ASU24		0.14 (0.03 to 0.59)	-14.79 (-39.97 to -2.67)
DCV12 + SOF12		0.40 (0.05 to 2.41)	-9.61 (-35.74 to 13.79)
SOF24 + LDV24 + RBV24	SOF12 + LDV12 + RBV12	1.25 (0.65 to 2.48)	1.73 (-3.70 to 8.23)
T12 PR24-48 RGT q8		4.06 (1.82 to 8.49)	21.38 (9.39 to 34.38)
T12 PR24-48 RGT q12		3.82 (1.56 to 8.47)	19.75 (6.02 to 35.44)
T12 PR48 q8		6.48 (2.70 to 14.03)	38.77 (17.91 to 61.81)
SOF12 + PR12		2.07 (0.91 to 4.84)	7.44 (-0.83 to 23.72)
SOF12 PR24-48 RGT		4.10 (1.54 to 10.01)	21.86 (5.92 to 42.99)
SIM12 PR24-48 RGT		2.87 (1.36 to 5.98)	13.08 (4.38 to 21.56)
B24 PR28-48 RGT		2.84 (1.24 to 6.19)	12.91 (2.74 to 24.07)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
B44 PR48		6.95 (1.39 to 19.84)	43.00 (3.62 to 82.55)
PR24		2.63 (0.79 to 7.90)	11.35 (-1.82 to 42.77)
SOF24 + RBV (low dose)		2.03 (0.79 10 7.90)	11.55 (-1.82 to 42.77)
24		0.17 (0.02 to 0.84)	-5.57 (-11.96 to -0.97)
PAR/RIT12 + OMB12		0.57 (0.18 to 1.66)	-2.95 (-10.13 to 3.34)
+ DAS12 PAR/RIT12 + OMB12			
+ DAS12 + RBV12		1.86 (0.79 to 4.06)	5.91 (-2.32 to 16.05)
DCV24 + ASU24		0.33 (0.10 to 1.04)	-4.59 (-11.55 to 0.18)
DCV12 + SOF12		0.94 (0.12 to 4.85)	-0.40 (-9.48 to 21.75)
T12 PR24-48 RGT q8	SOF24 + LDV24 + RBV24	3.22 (1.50 to 6.76)	19.56 (6.88 to 33.13)
T12 PR24-48 RGT q12		3.03 (1.28 to 6.66)	17.88 (3.79 to 34.04)
T12 PR48 q8		5.12 (2.24 to 11.13)	36.77 (15.97 to 60.15)
SOF12 + PR12		1.66 (0.71 to 3.85)	5.69 (-3.51 to 21.98)
SOF12 PR24-48 RGT		3.26 (1.25 to 7.90)	19.94 (3.26 to 41.56)
SIM12 PR24-48 RGT		2.29 (1.11 to 4.76)	11.32 (1.71 to 20.15)
B24 PR28-48 RGT		2.26 (1.03 to 4.93)	11.08 (0.40 to 22.58)
B44 PR48		5.44 (1.16 to 16.03)	41.21 (1.80 to 81.37)
PR24		2.10 (0.60 to 6.31)	9.60 (-4.28 to 41.35)
SOF24 + RBV (low dose) 24		0.13 (0.02 to 0.73)	-7.37 (-15.16 to -1.87)
PAR/RIT12 + OMB12 + DAS12		0.45 (0.15 to 1.34)	-4.71 (-13.19 to 2.03)
PAR/RIT12 + OMB12			
+ DAS12 + RBV12		1.47 (0.64 to 3.26)	4.08 (-5.10 to 14.36)
DCV24 + ASU24		0.26 (0.08 to 0.82)	-6.39 (-14.70 to -1.01)
DCV12 + SOF12		0.75 (0.10 to 3.77)	-2.11 (-12.51 to 19.93)
T12 PR24-48 RGT q12	T12 PR24-48 RGT q8	0.94 (0.66 to 1.25)	-1.59 (-10.08 to 7.10)
T12 PR48 q8		1.59 (0.82 to 2.97)	17.14 (-6.60 to 42.79)
SOF12 + PR12		0.51 (0.22 to 1.25)	-13.80 (-28.35 to 5.87)
SOF12 PR24-48 RGT		1.01 (0.47 to 2.08)	0.41 (-19.53 to 23.89)
SIM12 PR24-48 RGT		0.71 (0.44 to 1.19)	-8.25 (-22.07 to 3.73)
B24 PR28-48 RGT		0.70 (0.39 to 1.26)	-8.45 (-23.02 to 5.58)
B44 PR48		1.75 (0.39 to 3.99)	21.64 (-21.11 to 64.03)
PR24		0.66 (0.19 to 1.98)	-9.81 (-27.74 to 23.82)
SOF24 + RBV (low dose) 24		0.04 (0.00 to 0.23)	-27.13 (-40.45 to - 15.83)
PAR/RIT12 + OMB12 + DAS12		0.14 (0.06 to 0.29)	-24.44 (-35.11 to - 15.41)
PAR/RIT12 + OMB12		0.46 (0.22 to 0.93)	-15.39 (-29.92 to -1.45)
+ DAS12 + RBV12			. , ,
DCV24 + ASU24		0.08 (0.03 to 0.22)	–26.19 (–39.29 to – 15.38)
DCV12 + SOF12		0.24 (0.03 to 1.08)	-21.23 (-36.75 to 2.05)
T12 PR48 q8	T12 PR24-48 RGT q12	1.70 (0.83 to 3.52)	18.82 (-6.29 to 44.94)
SOF12 + PR12		0.54 (0.23 to 1.44)	-12.07 (-28.85 to 8.50)
SOF12 PR24-48 RGT		1.08 (0.47 to 2.43)	2.27 (-19.80 to 26.55)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SIM12 PR24-48 RGT		0.76 (0.44 to 1.42)	-6.55 (-22.93 to 6.91)
B24 PR28-48 RGT		0.75 (0.40 to 1.50)	-6.76 (-23.40 to 8.88)
B44 PR48		1.86 (0.39 to 4.65)	23.40 (-20.75 to 66.35)
PR24		0.70 (0.20 to 2.25)	-8.03 (-27.85 to 26.32)
SOF24 + RBV (low dose) 24		0.04 (0.01 to 0.26)	-25.43 (-41.37 to - 12.60)
PAR/RIT12 + OMB12 + DAS12		0.15 (0.07 to 0.34)	-22.78 (-36.68 to - 11.44)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.49 (0.22 to 1.10)	-13.73 (-30.56 to 1.78)
DCV24 + ASU24		0.09 (0.03 to 0.25)	-24.44 (-40.31 to - 12.08)
DCV12 + SOF12		0.25 (0.03 to 1.22)	-19.40 (-37.12 to 4.48)
SOF12 + PR12	T12 PR48 q8	0.32 (0.13 to 0.79)	-30.63 (-55.04 to -6.84)
SOF12 PR24-48 RGT		0.64 (0.29 to 1.43)	-16.41 (-44.68 to 13.15)
SIM12 PR24-48 RGT		0.44 (0.25 to 0.87)	-25.65 (-49.69 to -3.67)
B24 PR28-48 RGT		0.44 (0.23 to 0.88)	-25.74 (-50.25 to -3.43)
B44 PR48		1.11 (0.24 to 2.65)	4.95 (-44.17 to 51.76)
PR24		0.41 (0.12 to 1.25)	-26.43 (-53.63 to 8.47)
SOF24 + RBV (low dose) 24		0.03 (0.00 to 0.15)	-44.51 (-67.27 to - 24.40)
PAR/RIT12 + OMB12 + DAS12		0.09 (0.03 to 0.25)	-41.77 (-64.84 to - 21.10)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.29 (0.15 to 0.53)	-32.59 (-53.88 to - 14.10)
DCV24 + ASU24		0.05 (0.02 to 0.15)	-43.55 (-66.54 to - 23.33)
DCV12 + SOF12		0.15 (0.02 to 0.54)	-37.65 (-57.53 to - 18.62)
SOF12 PR24-48 RGT	SOF12 + PR12	1.98 (0.69 to 5.27)	14.05 (-8.24 to 37.09)
SIM12 PR24-48 RGT		1.39 (0.59 to 3.19)	5.62 (-12.76 to 16.56)
B24 PR28-48 RGT		1.38 (0.55 to 3.29)	5.37 (-13.30 to 18.34)
B44 PR48		3.22 (0.64 to 10.32)	34.61 (-7.66 to 77.45)
PR24		1.27 (0.50 to 2.94)	3.77 (-9.37 to 28.22)
SOF24 + RBV (low dose) 24		0.08 (0.01 to 0.39)	-13.12 (-29.48 to -5.20)
PAR/RIT12 + OMB12 + DAS12		0.27 (0.08 to 0.84)	-10.48 (-27.88 to -1.24)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.89 (0.39 to 2.03)	-1.52 (-17.64 to 8.82)
DCV24 + ASU24		0.16 (0.04 to 0.55)	-12.15 (-29.60 to -3.45)
DCV12 + SOF12		0.45 (0.05 to 2.30)	-7.46 (-26.31 to 13.98)
SIM12 PR24-48 RGT	SOF12 PR24-48 RGT	0.70 (0.35 to 1.50)	-8.74 (-30.99 to 8.21)
B24 PR28-48 RGT		0.69 (0.32 to 1.55)	-8.82 (-31.48 to 9.33)
B44 PR48		1.70 (0.35 to 4.87)	20.76 (-25.59 to 66.59)
PR24		0.65 (0.17 to 2.15)	-9.85 (-35.18 to 24.63)
SOF24 + RBV (low dose) 24		0.04 (0.01 to 0.26)	-27.53 (-48.08 to - 12.55)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
PAR/RIT12 + OMB12 + DAS12		0.14 (0.05 to 0.43)	-24.91 (-45.66 to -9.65)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.45 (0.19 to 1.12)	-15.77 (-38.28 to 2.18)
DCV24 + ASU24		0.08 (0.02 to 0.26)	–26.66 (–47.14 to – 11.80)
DCV12 + SOF12		0.24 (0.03 to 1.18)	-21.48 (-43.13 to 3.70)
B24 PR28-48 RGT	SIM12 PR24-48 RGT	0.99 (0.57 to 1.68)	-0.15 (-10.53 to 11.61)
B44 PR48		2.45 (0.57 to 5.49)	29.78 (-9.91 to 70.85)
PR24		0.92 (0.27 to 2.70)	-1.68 (-16.91 to 31.46)
SOF24 + RBV (low dose) 24		0.06 (0.01 to 0.32)	-18.86 (-26.73 to - 11.22)
PAR/RIT12 + OMB12 + DAS12		0.20 (0.07 to 0.50)	-16.19 (-24.21 to -8.29)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.65 (0.31 to 1.25)	-7.13 (-17.10 to 4.30)
DCV24 + ASU24		0.12 (0.05 to 0.27)	–17.82 (–24.81 to – 11.99)
DCV12 + SOF12		0.33 (0.05 to 1.52)	-13.31 (-23.76 to 9.47)
B44 PR48	B24 PR28-48 RGT	2.46 (0.55 to 6.05)	29.89 (-10.74 to 71.65)
PR24		0.94 (0.26 to 2.85)	-1.29 (-18.15 to 31.77)
SOF24 + RBV (low dose) 24		0.06 (0.01 to 0.34)	-18.63 (-29.85 to -9.39)
PAR/RIT12 + OMB12 + DAS12		0.20 (0.07 to 0.54)	-15.99 (-27.04 to -6.63)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.65 (0.30 to 1.40)	-6.98 (-19.67 to 5.76)
DCV24 + ASU24		0.12 (0.04 to 0.33)	-17.64 (-28.71 to -9.15)
DCV12 + SOF12		0.33 (0.05 to 1.56)	-13.02 (-25.83 to 9.53)
PR24	B44 PR48	0.40 (0.09 to 2.23)	-29.04 (-75.48 to 21.00)
SOF24 + RBV (low dose) 24		0.03 (0.00 to 0.21)	-48.76 (-87.50 to - 10.24)
PAR/RIT12 + OMB12 + DAS12		0.08 (0.02 to 0.45)	-46.28 (-85.21 to -7.48)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.26 (0.10 to 1.32)	-37.06 (-77.77 to 4.06)
DCV24 + ASU24		0.05 (0.01 to 0.26)	-47.96 (-86.62 to -9.64)
DCV12 + SOF12		0.14 (0.02 to 1.13)	-42.39 (-83.20 to 2.03)
SOF24 + RBV (low dose) 24	PR24	0.06 (0.01 to 0.34)	-17.15 (-48.34 to -4.45)
PAR/RIT12 + OMB12 + DAS12		0.22 (0.05 to 0.92)	-14.44 (-46.98 to -0.54)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.70 (0.23 to 2.33)	-5.44 (-36.40 to 9.21)
DCV24 + ASU24		0.13 (0.03 to 0.61)	-16.15 (-48.61 to -2.29)
DCV12 + SOF12		0.36 (0.04 to 2.52)	-11.15 (-44.14 to 13.46)
PAR/RIT12 + OMB12 + DAS12	SOF24 + RBV (low dose) 24	3.39 (0.50 to 31.87)	2.60 (-2.76 to 8.60)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
PAR/RIT12 + OMB12 + DAS12 + RBV12		11.22 (2.00 to 97.49)	11.56 (4.45 to 21.77)
DCV24 + ASU24		2.02 (0.28 to 20.02)	1.06 (-4.12 to 4.83)
DCV12 + SOF12		5.64 (0.44 to 63.09)	5.33 (-1.90 to 27.28)
PAR/RIT12 + OMB12 + DAS12 + RBV12	PAR/RIT12 + OMB12 + DAS12	3.26 (1.12 to 9.73)	8.90 (0.92 to 19.48)
DCV24 + ASU24		0.59 (0.15 to 2.21)	-1.59 (-7.40 to 2.58)
DCV12 + SOF12		1.69 (0.19 to 9.73)	2.65 (-5.71 to 25.00)
DCV24 + ASU24	PAR/RIT12 + OMB12 + DAS12 + RBV12	0.18 (0.06 to 0.55)	-10.54 (-21.08 to -3.47)
DCV12 + SOF12		0.52 (0.07 to 2.32)	-5.96 (-17.83 to 15.11)
DCV12 + SOF12	DCV24 + ASU24	2.82 (0.34 to 17.84)	4.21 (-2.49 to 26.70)
Random effect model	Residual deviance	62.47 vs. 64 data points	
	Deviance information criteria	371.62	
Fixed effect model	Residual deviance	63.66 vs. 64 data points	
	Deviance information criteria	371.027	

ASU = asunaprevir; B = boceprevir; BEC = beclabuvir; CrI = credible interval; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; GRZ = grazoprevir; LDV = ledipasvir; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; q8 = every 8 hours; q12 = every 12 hours; RBV = ribavirin; RD = risk difference; RGT = response-guided therapy; RIT = ritonavir; RR = relative risk; SIM = simeprevir; SOF = sofosbuvir; SVR = sustained virologic response; T = telaprevir; vs. = versus. Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.